Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Single-blind Treatment

PEAK PlasmaBlade™ vs. Traditional Electrosurgery in Abdominoplasty

Elastosis

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jan 2013
Primary outcome: Primary: Acute Thermal Injury Depth — 195; 763 micrometers — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
PEAK PlasmaBlade (Device); Standard of Care (SOC) (Procedure)
Age
Adult · 25+ yrs
Sex
All
Sponsor
Medtronic Surgical Technologies
Primary completion
Jun 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Acute Thermal Injury Depth
195; 763 <0.001 sig
PRIMARY
Inflammatory Cell Count
93; 120; 138; 207; 239; 171 0.33
SECONDARY
Total Drainage Output
654.89; 887.70 0.1128
SECONDARY
Change in Hemoglobin
-0.68; -1.62 0.0898
SECONDARY
Narcotic Consumption
3.82; 4.92; 2.39; 3.33 0.0760
SECONDARY
Postoperative Pain Levels
2.15; 3.30 0.4589
SECONDARY
Activity Level
452.78; 347.00 0.999
SECONDARY
Diet Volume
701.11; 470.50 0.0412 sig

Summary

The objective of this clinical study is to evaluate healing of incisions made with the PEAK PlasmaBlade 4.0 compared to scalpel and traditional electrosurgery (Bovie); to monitor and record key post-operative metrics following abdominoplasty with the PEAK PlasmaBlade 4.0 versus current standard of care (SOC); and to evaluate performance metrics of the PEAK PlasmaBlade 4.0 during abdominoplasty.

Eligibility Criteria

Inclusion Criteria

  • Age between 25 and 60 years old
  • Physically healthy, stable weight, non-smoker
  • Protruding abdomen, excess fat and skin and/or weak abdominal muscles qualifying for abdominoplasty.
  • Subject must understand the nature of the procedure and provide written informed consent prior to the procedure.
  • Subject must be willing and able to comply with specified follow-up evaluations.
  • Female subjects must either be no longer capable of reproduction or taking acceptable measures to prevent pregnancy during the study, and have a negative pregnancy test prior to participation in the study.

Exclusion Criteria

  • Age younger than 25 or greater than 60 years old
  • Anticoagulation therapy which cannot be discontinued
  • Smoking (any kind)
  • Diabetes (any type)
  • Infection (local or systemic)
  • Cognitive impairment or mental illness
  • Severe cardiopulmonary deficiencies
  • Known coagulopathy
  • Immunocompromised
  • Kidney disease (any type)
  • Subjects who are pregnant or lactating
  • Currently taking any medication known to affect healing
  • Subjects who are status-post gastric banding or gastric bypass
  • Reproductive age females who will not take acceptable measures to prevent pregnancy during the study.
  • Recent history of abdominal surgery or prior abdominoplasty.
  • Subjects who are known to be HIV or Hepatitis (any) positive
  • Currently enrolled in another investigational device or drug trial
  • Unable to follow instructions or complete follow-up
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00943150). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search